2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5412 Shorten-ctDNA: Early outcomes and quality of life after molecular residual disease-adapted de-escalation of frontline therapy for diffuse large B-cell lymphoma

Hua-Jay Jeffery Cherng, MD, Beatriz Raposo Corradini, MSc2, Ajay Major, MD, MBA3, Cheng-Shiun Leu, PhD4, Seda S. Tolu, MD5, Jennifer E. Amengual, MD6, Sandra Close, PhD7, Jacob Chabon, PhD8, Hayley Widden, PhD9, David Kurtz, MD, PhD10, Barbara Pro, MD11
1 Columbia University Irving Medical Center, New York, New York, United States
2 Columbia University Irving Medical Center, New York, New York, United States
3 University of Colorado, Aurora, Colorado, United States
4 Columbia University Irving Medical Center, New York, New York, United States
5 Columbia University Irving Medical Center, New York, New York, United States
6 Columbia University Irving Medical Center, New York, New York, United States
7 Natera, Inc, Austin, Texas, United States
8 Natera, Inc, Austin, Texas, United States
9 Natera, Inc, Austin, Texas, United States
10 Natera, Inc, Austin, Texas, United States
11 Columbia University Irving Medical Center, New York, New York, United States

Introduction
Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection is a clinically validated method of response assessment in diffuse large B-cell lymphoma (DLBCL). Patients (pts) with undetected ctDNA-MRD by phased variant (PV) enrichment and detection sequencing (PhasED-Seq) after 2 cycles of frontline therapy experienced a 2-year PFS rate of 96% (Roschewski JCO 2025). Real-time ctDNA-MRD testing with PhasED-Seq to guide de-escalation of frontline DLBCL therapy has not previously been performed. The benefits to quality of life (QoL) of de-escalation in DLBCL have also not been described.

Methods
SHORTEN-ctDNA is an ongoing single-center investigator-initiated feasibility study (NCT06693830) for pts with newly diagnosed stage II-IV DLBCL receiving standard R-CHOP or pola-R-CHP. Whole blood samples were drawn on cycle 4 day 1 (C4D1) for real-time ctDNA-MRD testing. These samples, alongside biopsy tissue to identify pt-specific PVs, were analyzed with PhasED-Seq (CLARITY, Foresight). PET scans were performed on C4D15 (iPET4). Pts with undetected ctDNA-MRD on C4D1 and complete metabolic response (CMR) on iPET4 received rituximab alone for C5-6. All other pts continued standard therapy. Equivocal iPET4 response could be adjudicated with biopsy for de-escalation eligibility. Exploratory pt-reported outcomes (PRO) analyses were performed.

Results
We report on updated outcomes on the first 16 evaluable pts. Median age was 68 years (40-92), 13 (81%) were stage III-IV, 10 (63%) had elevated lactate dehydrogenase (LDH), 8 (50%) had ≥2 extranodal sites, and 5 (31%) had bulky tumor ≥7.5 cm. The international prognostic index (IPI) was ≥3 for 9 (56%). Four pts received R-CHOP (25%) and 12 pola-R-CHP (75%).

Of the 16 pts, 15/16 (94%) had pt-specific PVs identified, and those 15 had successful real-time ctDNA-MRD testing. Median time from sample collection to results reporting was 8 days (7-11). A median 10 mL plasma was used from each sample, enabling a median empirical sensitivity of 0.96 parts per million (0.38-5.21). The rate of undetected ctDNA-MRD on C4D1 was 10/15 (67%); of these 10 pts, 7 (70%) were stage IV, 6 (60%) had elevated LDH, 5 (50%) had ≥2 extranodal sites, 3 (30%) had bulky tumor, and 5 (50%) had IPI ≥3. There were no significant differences between pts by ctDNA-MRD status. iPET4 was equivocal for 4/10; these 4 pts had biopsies showing inflammation (3) or benign tissue (1) confirming CMR before de-escalation. Residual FDG-avid sites resolved in 3 and persisted in 1 by end-of-treatment (EOT). All 10 pts with undetected ctDNA-MRD at C4D1 de-escalated to rituximab for C5-6, and 5 pts with detected ctDNA-MRD and one with unsuccessful testing continued standard therapy. After a median follow-up of 9.8 months (2.8-18.6), all pts (de-escalated and standard) remain in remission. Additional analysis of follow-up ctDNA-MRD data from banked samples is ongoing and will be presented.

PRO tools were administered on C4D1 and at EOT: EORTC QLQ-C30 (global health status and single summary score, range 0-100; higher scores reflect better QoL), FACIT item GP5 (overall side-effect burden, score 0-4; higher scores reflect greater burden), and a 20-item PRO-CTCAE instrument with composite scores (range 0-3, absent to very severe) calculated for individual adverse events (AE).

From C4D1 to EOT, mean QLQ-C30 global health status scores were stable with de-escalation (75 to 75) but worsened with standard therapy (60 to 54). Mean QLQ-C30 summary scores showed a similar trend (de-escalation: 83 to 82; standard: 78 to 70). Mean FACIT GP5 scores were stable with de-escalation (1.3 to 1.1) but worsened with standard therapy (2.8 to 3.3). Rates of PRO-CTCAE composite scores ≥2 from C4D1 to EOT for de-escalated vs standard pts, respectively, were: dysgeusia (33% to 20% [de-escalated] vs 83% to 60% [standard]), appetite (22% to 20% vs 50% to 40%), constipation (11% to 10% vs 33% to 80%), pain (11% to 20% vs 50% to 40%), headache (0% to 20% vs 17% to 60%), and fatigue (11% to 30% vs 33% to 60%).

Conclusion
Results from the ongoing SHORTEN-ctDNA study suggest that real-time ctDNA-MRD assessment to de-escalate frontline therapy in DLBCL is feasible. Short-term outcomes for the two-thirds of pts with undetected ctDNA-MRD on C4D1 who stopped chemotherapy early are excellent. For pts who underwent de-escalation, QoL remained stable from a high baseline, side effect burden decreased over time, and pt-reported AEs at EOT were mild.
Hua-Jay Jeffery Cherng, MD: Foresight Diagnostics - Honoraria; Natera - Honoraria; ADC Therapeutics - Research Funding; Natera - Consultancy (Includes expert testimony); Foresight Diagnostics - Consultancy (Includes expert testimony)